Full-Time

Associate Director

US Commercial Insights, Rheumatology

Updated on 8/25/2026

argenx

argenx

1,001-5,000 employees

Biotech immunology company developing therapeutic antibodies

Compensation Overview

$168k - $231k/yr

+ Short-term incentive program + Long-term incentive program

Remote in USA

Remote

Remote within the United States, with travel up to 20% of the time.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Market Research
Quantitative Research
Data Analysis

Get referred to argenx

See people who can refer or advise you

Requirements
  • A BA or BS is required; an advanced degree is preferred.
  • Seven to ten years of experience in pharmaceutical, biotechnology, healthcare market insights, or relevant commercial functions is required.
  • Demonstrated expertise conducting primary market research is required.
  • Expertise in a broad range of qualitative and quantitative market research methodologies is required.
  • Strong analytical skills with the ability to define business issues and recommendations are required.
  • Ability to collaborate with cross-functional teams, including stakeholders in commercial and medical organizations.
  • Ability to influence senior stakeholders and shape strategic decisions in a matrixed environment.
  • Ability to integrate disparate data sources into clear, strategic narratives that drive business impact.
  • Ability to think strategically over the long term and evolve research methods to elevate the role of insights in commercial decision-making.
  • Ability to identify business opportunities and develop research plans that provide actionable insights.
  • Ability to travel up to 20% of the time.
  • Familiarity with leading pharmaceutical industry commercial vendors and data sources.
Responsibilities
  • Own and define the United States insights strategy and learning agenda for the rheumatology portfolio.
  • Partner with cross-functional and global commercialization partners to identify market intelligence needs and deliver insights supporting market development and go-to-market strategies.
  • Translate business questions into structured research plans and learning agendas supporting the rheumatology team.
  • Ensure methodological rigor and best practices across qualitative and quantitative, primary and secondary research activities.
  • Synthesize insights across market research, competitive intelligence, analytics, and field insights to deliver an integrated view of the market and customer.
  • Act as a trusted advisor to cross-functional leadership across commercial, medical, analytics, and market access.
  • Drive alignment across United States and global stakeholders on key insights and strategic implications.
  • Ensure insights influence business decisions, including strategy, positioning, and go-to-market approach.
  • Contribute to innovative approaches for insights generation, including new methodologies, tools, and data sources.
  • Lead continuous improvement of how insights are generated, synthesized, and applied to strategy.
  • Manage vendor partnerships with a focus on quality, innovation, and value creation.
  • Partner with Finance and the Director of Commercial Insights to manage the department budget, vendor agreements, and contracts.
Desired Qualifications
  • Primary market research experience in rare disease.
  • Launch experience in rare disease and/or rheumatology.

argenx develops antibody therapies to treat autoimmune diseases and cancer by translating scientific discoveries in immunology into therapeutic antibodies. Its work centers on R&D and then licensing and collaborations for commercialization, with cusatuzumab being developed with Janssen R&D to target hematological cancers such as leukemia. The company funds and accelerates discovery mainly through partnerships and licenses, bringing products to market via partner-based commercialization rather than building its own sales force. Its goal is to advance antibody-based treatments for serious autoimmune diseases and cancer by turning scientific insights into clinically useful therapies through industry and academic collaborations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales hit $1.5 billion, up 60%, with $494 million operating profit.
  • May 8, 2026 FDA approval expanded VYVGART to anti-AChR, MuSK, LRP4, and seronegative patients.
  • August 2026 ALKIVIA Phase 3 results strengthened VYVGART Hytrulo’s autoimmune myositis expansion path.

What critics are saying

  • FDA issued two January 30, 2026 untitled letters over misleading VYVGART HYTRULO TV ads.
  • VYVGART remains concentration risk; a safety, pricing, or reimbursement hit would damage 2027 growth.
  • The $2.2 billion Forte acquisition must close by Q3 2026 or management credibility weakens.

What makes argenx unique

  • VYVGART became the first approved FcRn blocker across all adult gMG serotypes in May 2026.
  • argenx pairs global commercialization with SIMPLE Antibody and strong academic partnership infrastructure.
  • The July 2026 Forte deal adds FB102, broadening immunology reach beyond FcRn biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
wallstreet:online AG
Aug 21st, 2026
Not Moderna: this biotech stock still has potential after an 11,000% rally!

Not Moderna: this biotech stock still has potential after an 11,000% rally! Since its IPO in 2014, the Argenx stock has risen by more than 11,150 percent. A study success is fueling new enthusiasm for Argenx. The background. Photo: Andrew Brookes - Westend61 Europe's largest listed pure-play biotech group currently knows only one direction: upwards. The Argenx stock has gained 21 percent since last Friday's closing price, marked a record high and is heading for its best week in more than three years. This puts it at the top of the winners in the Stoxx Europe 600, reports Bloomberg. The long-term record is even more spectacular: Since the Brussels listing in July 2014, the price has shot up by more than 11,150 percent. The market capitalization climbed to 55.4 billion euros - putting Argenx ahead of Moderna again. Trade your assessment of BioNTech SE ADR!

Yahoo Finance
Aug 18th, 2026
Argenx rises 11.5% after positive phase 3 trial for autoimmune myositis treatment

argenx reported positive Phase 3 results for its ALKIVIA trial evaluating VYVGART Hytrulo in adults with autoimmune myositis. The trial met its primary endpoint, with patients showing statistically significant improvements in Total Improvement Score over 52 weeks versus placebo. The study marks the first Phase 3 trial demonstrating benefit in immune-mediated necrotizing myopathy, a subtype with no approved targeted therapies. The safety profile remained consistent with prior studies. The company recently received US FDA priority review for VYVGART in seronegative generalized myasthenia gravis, with a decision expected on 10 May 2026. These label expansions could broaden VYVGART's reach across multiple autoimmune conditions. argenx's shares rose 11.5% following the announcement. The company's narrative projects $9.7 billion revenue and $3.5 billion earnings by 2029, requiring 22.3% yearly revenue growth.

Yahoo Finance
Aug 11th, 2026
argenx shares up 39% in a year, but analysts debate $775 fair value vs $867 close

argenx, a commercial-stage biopharma company specialising in autoimmune disease treatments, has attracted investor attention following recent share price movements. The stock closed at €767, up approximately 6% over the past week and 38.6% over the past year, bringing its market value to around €47.97 billion. The company generates revenue of €5.3 billion, primarily from its VYVGART franchise, with operations spanning the United States, Japan, China, and other markets. According to a widely followed valuation narrative, argenx appears 11.7% overvalued, with a fair value estimate of €686.43. The analysis credits the company's leadership in FcRn inhibitors and strong commercial growth, whilst noting typical biotech risks including single-asset dependence and pricing pressure. Revenue has doubled over two years, supporting the growth thesis.

National Tribune
Aug 5th, 2026
argenx signs new strategic partnership agreement with Monash-originated biotechnology company Myostellar.

argenx signs new strategic partnership agreement with Monash-originated biotechnology company Myostellar. * Education * 6 Aug 2026 8:33 am AEST * Share Monash University Global immunology company argenx has entered into a new strategic partnership agreement with Monash University and Monash-originated spinout Myostellar, to develop novel first in class molecules for muscular therapeutic areas. This new agreement builds on the existing strategic research and innovation partnership between Monash and argenx from earlier this year and demonstrates both organisations' commitment to advancing novel scientific research in the interest of patients. In 2022 Myostellar received $500,000 through the inaugural funding round of Brandon Biocatalyst's CUREator program, Australia's national biotechnology incubator, to support the development of regenerative therapies for muscular dystrophies, alongside investment from Monash Investment Holdings. In 2025, it was one of the inaugural recipients of the Monash Ventures Pre-Seed Fund, a $15 million initiative developed by Monash University in partnership with Breakthrough Victoria. Myostellar continues to be governed by Monash Investment Holdings nominee directors Dr Alison Greenway, Associate Dean and Senior Director, Enterprise and Partnerships, MNHS, and Dr Callum Benson, Investment Director, Monash Ventures. argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. The company has a long-standing history and track record of partnering with leading academic and clinical researchers through its Immunology Innovation Program (IIP) to translate scientific breakthroughs into a portfolio of novel antibody-based medicines. Professor Currie and Professor Martino said: "As researchers, our goal has always been to see our discoveries create meaningful impact for patients. We're proud to be partnering with argenx to help realise that ambition with the support of Monash's business and commercialisation teams." Dr Andrea Huggins, Vice-President (Innovation and Commercialisation), said: "It's outstanding to see Myostellar's trajectory from company formation to early-stage investment and global industry partnership, informed by Monash's commercialisation talent and capabilities." Dr Greenway said: "This research collaboration agreement with argenx represents a powerful endorsement of the depth of expertise, capability and globally recognised talent across medicine and health sciences at Monash." City & Local Guides Kathryn Evans, General Manager, Australia at argenx, said: "National Tribune is very pleased to further strengthen argenx's relationship with Monash through the new research collaboration, enabling National Tribune to access and deeply engage with Australia's world-class research community. "Built on transparency, long-term commitment, and shared success, our Immunology Innovation Program reflects how argenx works best - side-by-side with collaborators, advancing science that has the potential to define what's possible for patients. We look forward to working with Monash and Myostellar and bringing together their scientific expertise with argenx's global development capabilities." The agreement builds on the strategic research and innovation partnership between Monash and argenx announced in January 2026. The earlier partnership brought together Monash research expertise and argenx's development capabilities to advance an antibody molecule in preclinical development. Discover more City & Local Guides Southeast Asians & Pacific Islanders

Forte Biosciences
Jul 27th, 2026
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction argenx (Euronext Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’